Portal de Periódicos da CAPES

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

2010; Elsevier BV; Volume: 24; Issue: 6 Linguagem: Inglês

10.1016/j.blre.2010.08.003

1532-1681

Ádám Jóna, Anas Younes,

Chronic Lymphocytic Leukemia Research

The treatment of patients with relapsed and refractory Hodgkin lymphoma (HL), especially those who relapse after autologous stem cell transplantation, remains challenging.Patients with HL whose disease relapses after stem cell transplantation are rarely cured with current treatment modalities, and have a median survival is less than 3 years.With no new drugs have been approved by the FDA for HL in more than three decades, there is a clear unmet medical need for drug development for this patients population.New treatment strategies that are based on targeting oncogenic signaling pathways are currently explored.This review will focus on emerging new treatment modalities that are currently under investigation for patients with relapsed classical HL.